DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Humira (Adalimumab) - Published Studies

 
 



Humira Related Published Studies

Well-designed clinical trials related to Humira (Adalimumab)

Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis. [2012]

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. [2012]

Abatacept for Crohn's disease and ulcerative colitis. [2012]

Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. [2012]

Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. [2012]

Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. [2011.11.30]

Adalimumab Induces and Maintains Clinical Remission in Patients with Moderate-to-Severe Ulcerative Colitis. [2011.11.03]

Adalimumab (anti-TNF-alpha) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study. [2011.10.20]

Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. [2011.10]

Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. [2011.09]

311 nm ultraviolet B-accelerated response of psoriatic lesions in adalimumab-treated patients. [2011.08]

A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. [2011.08]

Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. [2011.07]

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. [2011.06]

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. [2011.05.24]

IBD: Adalimumab for ulcerative colitis- is the glass half empty or half full? [2011.05]

Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis. [2011.05]

Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. [2011.04]

Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study. [2011.02.27]

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. [2011.02.01]

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. [2011.02]

Adalimumab in ulcerative colitis: hypes and hopes. [2011.01]

Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. [2011.01]

Update on the management of inflammatory bowel disease: specific role of adalimumab. [2011]

A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. [2011]

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. [2010.12.07]

Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. [2010.11]

Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo. [2010.09.03]

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. [2010.09]

Adalimumab in severe and acute sciatica: a multicenter, randomized, double-blind, placebo-controlled trial. [2010.08]

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. [2010.08]

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. [2010.06]

Dosage adjustment during long-term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics. [2010.05.10]

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. [2010.05]

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. [2010.04]

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. [2010.04]

Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. [2010.02]

Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. [2010.02]

Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. [2010.01]

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. [2010]

Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. [2010]

Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. [2010]

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. [2009.11]

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. [2009.11]

A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. [2009.08]

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. [2009.07]

Adalimumab for the treatment of fistulas in patients with Crohn's disease. [2009.07]

Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. [2009.07]

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. [2009.06]

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. [2009.05]

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). [2009.05]

Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. [2009.04]

Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. [2009.04]

Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. [2009]

Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. [2008.12.09]

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. [2008.12]

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. [2008.11]

Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. [2008.10.15]

Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. [2008.10.15]

Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. [2008.10.02]

Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. [2008.10]

Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial. [2008.09]

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. [2008.08.21]

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. [2008.07]

Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). [2008.07]

Adalimumab Reduces Pain, Fatigue, and Stiffness in Patients with Ankylosing Spondylitis: Results from the Adalimumab Trial Evaluating Long-Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS). [2008.05.15]

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. [2008.03]

Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. [2008.02]

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. [2008.01]

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. [2008]

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. [2007.11.28]

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. [2007.11]

Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. [2007.11]

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. [2007.10.11]

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. [2007.09]

Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. [2007.08.15]

Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study. [2007.07.30]

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. [2007.06.19]

Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab. A Randomized Trial. [2007.04.30]

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. [2007.02]

Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. [2007]

Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. [2006.10]

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. [2006.07]

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. [2006.06]

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. [2006.02]

Safety Analyses of Adalimumab (HUMIRA(R)) in Global Clinical Trials and US Postmarketing Surveillance of Patients With Rheumatoid Arthritis. [2006.01.26]

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. [2006.01]

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. [2005.10]

Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. [2005]

Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. [2004.06]

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. [2004.05]

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. [2004.05]

Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. [2004]

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). [2003.12]

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. [2003.12]

Role of adalimumab in the treatment of early rheumatoid arthritis. [2003.09]

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. [2003.06]

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. [2003.01]

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. [2002.11]

Well-designed clinical trials possibly related to Humira (Adalimumab)

Defining the Minimally Important Change for the SpondyloArthritis Research Consortium of Canada Spine and Sacroiliac Joint Magnetic Resonance Imaging Indices for Ankylosing Spondylitis. [2012]

Modern treatment strategies in rheumatoid arthritis. [2011.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014